Article Text

other Versions

PDF
Systematic review
The new oral anticoagulants: practical management for patients attending for endoscopic procedures
  1. C Woodhouse1,
  2. G Evans2,
  3. A F Muller1
  1. 1Department of Gastroenterology, The Kent and Canterbury Hospital, Canterbury, Kent, UK
  2. 2Department of Haemophilia, The Kent and Canterbury Hospital, Canterbury, Kent, UK
  1. Correspondence to Dr A F Muller, Department of Gastroenterology, Kent and Canterbury Hospital, Ethelbert Road, Canterbury, Kent CT1 3NG, UK; andrew.muller{at}nhs.net

Abstract

Guidelines published by the British Society of Gastroenterology have standardised the care of patients attending for endoscopy procedures, taking aspirin, clopidogrel and warfarin.

Two new oral anticoagulant drugs, Rivaroxaban and Dabigatran, are licensed and National Institute of Clinical Excellence (NICE) approved for use in the UK. Unlike warfarin, these drugs do not require regular monitoring, and are at least as effective in preventing stroke in non-valvular atrial fibrillation. As such, they are likely to become popular among patients and clinicians alike. This paper summarises the practical management of patients taking these drugs attending for endoscopic procedures.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles